Warren Buffett Comments on Valeant Pharma (VRX)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- SK Hynix’s record plunge drags down global chip stocks
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- Ditching streaming could boost Disney stock by 40%, Wells Fargo says
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
Valeant (VRX) 10-K Not Enough to Bring Back the Bulls or Scare The Bears - BMO Capital
May 2, 2016 9:56 AM EDTBMO Capital analyst Alex Arfaei reiterated a Market Perform rating and lowered his price target on Valeant Pharmaceuticals (NYSE: VRX) to $44.00 (from $66.00), saying the 10K is not enough to bring back the bulls or scare the bears.
Arfaei commented, "The good news was that we didnt find any new smoking guns in the 10-K. Valeant has averted technical default on its debt, and based on our... More
Valeant's (VRX) Debt Covenants Remain a Concern After 10K Filing - Piper Jaffray
May 2, 2016 7:43 AM EDTPiper Jaffray analyst, David Amsellem, noted that Valeant's (NYSE: VRX) 10K for 2015 contained one kernel of good news: it cured the default on its senior notes related to the late filing. Unfortunately that was "the only piece of good news". Here are the problems:
Wholesaler inventory... More
